Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn's disease

1. Sheehan D, Moran C, Shanahan F. The microbiota in inflam-

www.irjournal.org

matory bowel disease. J Gastroenterol 2015;50:495-507.

2. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol

2014;49:785-798.

3. Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A.

Gut microbiota in the pathogenesis of inflammatory bowel

disease. Clin J Gastroenterol 2018;11:1-10.

4. Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: east meets west. J Gastroenterol

Hepatol 2020;35:380-389.

5. Ananthakrishnan AN. Epidemiology and risk factors for IBD.

Nat Rev Gastroenterol Hepatol 2015;12:205-217.

6. Kaplan GG, Ng SC. Understanding and preventing the global

increase of inflammatory bowel disease. Gastroenterology

2017;152:313-321.

7. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594.

8. Takahashi K, Nishida A, Fujimoto T, et al. Reduced abundance

of butyrate-producing bacteria species in the fecal microbial

community in Crohn’s disease. Digestion 2016;93:59-65.

9. Nagalingam NA, Lynch SV. Role of the microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2012;18:968-984.

10. Frank DN, Robertson CE, Hamm CM, et al. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm

Bowel Dis 2011;17:179-184.

11. Nishino K, Nishida A, Inoue R, et al. Analysis of endoscopic

brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease. J Gastroenterol 2018;53:95-106.

12. Litvak Y, Byndloss MX, Tsolis RM, Bäumler AJ. Dysbiotic Proteobacteria expansion: a microbial signature of epithelial dysfunction. Curr Opin Microbiol 2017;39:1-6.

13. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics

of the gut microbial ecosystem in inflammatory bowel diseases. Nature 2019;569:655-662.

14. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018;15:111-128.

15. Sinha SR, Haileselassie Y, Nguyen LP, et al. Dysbiosis-induced

secondary bile acid deficiency promotes intestinal inflammation. Cell Host Microbe 2020;27:659-670.

16. Begley M, Gahan CG, Hill C. The interaction between bacteria

and bile. FEMS Microbiol Rev 2005;29:625-651.

17. Franzosa EA, Sirota-Madi A, Avila-Pacheco J, et al. Gut microbiome structure and metabolic activity in inflammatory bow-

379

Shigeki Bamba, et al. • Ileal gut microbiota and bile acids in CD

el disease. Nat Microbiol 2019;4:293-305.

18. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key

actors in inflammatory bowel disease. Nat Rev Gastroenterol

Hepatol 2020;17:223-237.

19. Duboc H, Rajca S, Rainteau D, et al. Connecting dysbiosis, bileacid dysmetabolism and gut inflammation in inflammatory

bowel diseases. Gut 2013;62:531-539.

20. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of

a Crohn’s disease activity index. National Cooperative Crohn’s

Disease Study. Gastroenterology 1976;70:439-444.

21. Hasegawa M, Inohara N. Regulation of the gut microbiota by

the mucosal immune system in mice. Int Immunol 2014;26:

481-487.

22. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur:

open-source, platform-independent, community-supported

software for describing and comparing microbial communities. Appl Environ Microbiol 2009;75:7537-7541.

23. Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knight

R. Bacterial community variation in human body habitats across

space and time. Science 2009;326:1694-1697.

24. Murakami M, Iwamoto J, Honda A, et al. Detection of gut dys-

380

biosis due to reduced Clostridium subcluster XIVa using the

fecal or serum bile acid profile. Inflamm Bowel Dis 2018;24:

1035-1044.

25. Shoda J, Mahara R, Osuga T, et al. Similarity of unusual bile

acids in human umbilical cord blood and amniotic fluid from

newborns and in sera and urine from adult patients with cholestatic liver diseases. J Lipid Res 1988;29:847-858.

26. Nagayama M, Yano T, Atarashi K, et al. TH1 cell-inducing Escherichia coli strain identified from the small intestinal mucosa of

patients with Crohn’s disease. Gut Microbes 2020;12:1788898.

27. Johansson ME, Hansson GC. Immunological aspects of intestinal mucus and mucins. Nat Rev Immunol 2016;16:639-649.

28. Litvak Y, Byndloss MX, Bäumler AJ. Colonocyte metabolism

shapes the gut microbiota. Science 2018;362:eaat9076.

29. Baumgart DC, Sandborn WJ. Inflammatory bowel disease:

clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657.

30. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 2016;7:22-39.

www.irjournal.org

https://doi.org/10.5217/ir.2021.00054 • Intest Res 2022;20(3):370-380

See “Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease” on

pages 370-380.

Supplementary Table 1. Background Characteristics of Crohn’s Disease

Characteristics

Inactive (n = 18)

Active (n = 9)

Sex (male/female)

14/4

7/2

Age (yr), median (IQR)

35.1 (31.9–47.0)

47.4 (35.3–60.7)

Body mass index (kg/m2), median (IQR)

21.2 (18.6–24.5)

21.7 (20.2–23.5)

Smoking status (never/previous/current)

12/3/3

7/2/0

History of intestinal resection (yes/no)

Disease duration (yr), median (IQR)

Disease location (L1/L2/L3)

Disease behavior (B1/B2/B3)

3/15

0/9

9.5 (6.6–14.5)

14.6 (1.6–33.0)

9/1/8

4/0/5

9/7/2

1/5/3

62.0 (46.5–83.7)

66.0 (48.0–96.0)

Crohn’s disease

18

Gastrointestinal bleeding

Intestinal neoplasia

Other

3 (16.7)

2 (22.2)

CDAI, median (IQR)

Disease

Medication, No. (%)

Proton pump inhibitors

Probiotics

6 (33.3)

4 (44.4)

5-ASA/SASP

11 (61.1)

7 (77.8)

Prednisolone

1 (5.6)

10 (55.6)

3 (33.3)

6 (33.3)

3 (33.3)

Immunomodulators

Biologics

IQR, interquartile range; L1, ileal; L2, colonic; L3, ileocolonic; B1, non-stricturing, non-penetrating; B2, stricturing; B3, penetrating; CDAI, Crohn’s disease

activity index; 5-ASA, 5-aminosalicylates; SASP, sulfasalazine.

www.irjournal.org

Shigeki Bamba, et al. • Ileal gut microbiota and bile acids in CD

Supplementary Table 2. Comparison of Bile Acid Fraction between Active and Inactive CD

Bile acids (%)

Median (IQR)

P -value

Inactive (n = 25)

Active (n = 8)

CA

11.10 (4.51–47.70)

12.10 (4.68–38.80)

0.983

GCA

33.0 (11.3–55.7)

40.9 (26.3–54.2)

0.883

TCA

2.890 (0.654–4.580)

2.090 (0.983–6.700)

0.412

CDCA

2.00 (0.71–5.63)

3.47 (1.28–18.00)

0.185

GCDCA

10.80 (4.33–18.60)

18.60 (8.18–26.30)

0.265

TCDCA

1.140 (0.287–4.030)

2.690 (0.692–4.580)

0.462

0.840 (0.158–1.490)

0.185

DCA

1.920 (0.267–7.270)

GDCA

0.46400 (0.04670–3.95000)

0.01680 (0.00399–0.23800)

0.046

TDCA

0.07270 (0.00815–0.31900)

0.01210 (0.00298–0.15200)

0.344

LCA

0.639 (0.212–4.400)

0.529 (0.304–1.810)

0.629

GLCA

0.00443 (0.00145–0.02680)

0.00217 (0.00169–0.00667)

0.159

TLCA

0.01000 (0.00217–0.07730)

0.00614 (0.00252–0.00887)

0.437

UDCA

0.531 (0.037–1.380)

0.387 (0.191–1.160)

0.850

GUDCA

0.331 (0.134–4.080)

1.710 (0.508–5.830)

0.185

TUDCA

0.0356 (0.0107–0.3360)

0.0225 (0.0116–0.3100)

0.659

CD, Crohn’s disease; IQR, interquartile range; CA, cholic acid; GCA, glycocholic acid; TCA, taurocholic acid; CDCA, chenodeoxycholic acid; GCDCA, glyco­

chenodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; DCA, deoxycholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; LCA,

litho­cholic acid; GLCA, glycolithocholic acid; TLCA, taurolithocholic acid; UDCA, ursodeoxycholic acid; GUDCA, glycoursodeoxycholic acid; TUDCA, tauro­

ursodeoxycholic acid.

P-values were calculated using the Mann-Whitney U test.

www.irjournal.org

...